VPC
STRO icon

Vestal Point Capital’s Sutro Biopharma STRO Stock Holding History

Vestal Point Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-243,000
Closed -$2.81M – 110
2025
Q4 		$2.81M Sell
243,000
-17,000
-7% -$161K 0.1% 67
2025
Q3 		$2.26M Hold
260,000
– – 0.1% 76
2025
Q2 		$1.86M Hold
260,000
– – 0.1% 63
2025
Q1 		$1.69M Buy
260,000
+3,000
+1% +$47.2K 0.12% 56
2024
Q4 		$4.73M Buy
+257,000
New +$7.85M 0.28% 55

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vestal Point Capital's STRO Position: Q1 2026 in Review

Vestal Point Capital sold out of Sutro Biopharma (STRO) in Q1 2026, closing a stake of 243,000 shares — an estimated $2.81M sold.

Vestal Point Capital first reported a position in STRO in Q4 2024 and held it in 5 quarters. The position peaked at $4.73M in Q4 2024. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Vestal Point Capital reported no remaining Sutro Biopharma position as of Q1 2026 after selling out during the quarter.
  • Vestal Point Capital sold 243,000 Sutro Biopharma shares in Q1 2026, an estimated $2.81M.
  • Vestal Point Capital first reported a position in Sutro Biopharma in Q4 2024 and held it in 5 quarters.
  • Vestal Point Capital's Sutro Biopharma position peaked at $4.73M in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.